Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 5/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20907580 | 1.00 | JAK1 (0.36) | JAK1EP300RETMKNK1MKNK2 | |
| SCHEMBL28403736 | 0.88 | MKNK1 (0.35) | EP300RETMKNK1MKNK2CREBBP | |
| SCHEMBL28403738 | 0.88 | MKNK1 (0.35) | EP300RETMKNK1MKNK2CREBBP | |
| SCHEMBL20908223 | 0.86 | MKNK1 (0.32) | EP300MKNK1MKNK2CREBBPBRD4 | |
| SCHEMBL29640359 | 0.86 | MKNK1 (0.32) | EP300MKNK1MKNK2CREBBPBRD4 | |
| SCHEMBL30557222 | 0.83 | BRD4 (0.35) | EP300RETMKNK1MKNK2CREBBP | |
| SCHEMBL21150320 | 0.83 | MKNK1 (0.34) | EP300RETMKNK1MKNK2CREBBP | |
| SCHEMBL30557239 | 0.77 | EP300 (0.41) | JAK1EP300RETCREBBPBRD4 | |
| SCHEMBL28404543 | 0.76 | CTSS (0.34) | EP300 | |
| SCHEMBL21112970 | 0.75 | CREBBP (0.36) | EP300RETMKNK1MKNK2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | JAK1 935/4885EP300 880/4885RET 4730/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | JAK1 975/4885EP300 1399/4885RET 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.